Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018 Aug 18;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Venney D, Mohd-Sarip A, Mills KI. The impact of epigenetic modifications in myeloid malignancies. Int J Mol Sci. 2021 May 9;22(9):5013.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016 Jan 7;127(1):53–61.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Kadia TM, DiNardo CD, et al. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 Apr 15;127(8):1186–1207.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020 May 13;10(5):56.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019 Jul;36:70–87.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014 Aug 20;32(24):2541–2552.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013 May 30;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yokoyama K, Shimizu E, et al. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019 Jun 20;133(25):2682–2695.
   PubMed Web of Science ®Google Scholar
• Carbonell D, Suarez-Gonzalez J, Chicano M, et al. Next-generation sequencing improves diagnosis, prognosis and clinical management of myeloid neoplasms. Cancers. 2019 Sep 13;11(9):1364.
   PubMed Web of Science ®Google Scholar
• Neri F, Rapelli S, Krepelova A, et al. Intragenic DNA methylation prevents spurious transcription initiation. Nature. 2017 Mar 2;543(7643):72–77.
   PubMed Web of Science ®Google Scholar
• Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer. 2012 Jan 17;106(2):248–253.
   PubMed Web of Science ®Google Scholar
• Lund K, Cole JJ, VanderKraats ND, et al. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol. 2014 Aug 30;15(8):406.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Fenaux P, Gobbi M, et al. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022 Jul 21;140(3):285–289.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang X, Yu H, et al. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations. Onco Targets Ther. 2018;11:6863–6870.
   PubMed Web of Science ®Google Scholar
• Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011 Aug 11;118(6):1472–1480.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Jing Y, et al. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2020 Mar 1;146(5):1457–1467.
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012 Dec;6(6):579–589.
   PubMed Web of Science ®Google Scholar
• Singh AK, Bishayee A, Pandey A. Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy. Nutrients. 2018 Jun 6;10(6):731.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Santos FPS, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011 Feb;25(2):226–235.
   PubMed Web of Science ®Google Scholar
• Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.
   PubMed Web of Science ®Google Scholar
• Autin P, Blanquart C, Fradin D. Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancers. 2019 Oct 10;11(10):1530.
   PubMed Web of Science ®Google Scholar
• Zhao L, Lv C, Sun L, et al. Histone deacetylase inhibitor chidamide regulates the Wnt/beta-catenin pathway by MYCN/DKK3 in B-ALL. Invest New Drugs. 2021 Aug;39(4):961–970.
   PubMed Web of Science ®Google Scholar
• Liu J, Lv N, Zhou L, et al. Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway. Transl Cancer Res. 2020 Feb;9(2):827–839.
   PubMed Web of Science ®Google Scholar
• Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. Am J Transl Res. 2016;8(7):3169–3178.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016 Jan 7;127(1):42–52.
   PubMed Web of Science ®Google Scholar
• Blagitko-Dorfs N, Schlosser P, Greve G, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019 Apr;33(4):945–956.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou J, Wang L, et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013;8(8):e70522.
   PubMed Web of Science ®Google Scholar
• Mao J, Li S, Zhao H, et al. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines. Am J Transl Res. 2018;10(8):2567–2578.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2019 Jun 1;17(6):721–749.
   PubMed Web of Science ®Google Scholar
• Zhu JF, Dai HP, Zhang QQ, et al. Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. Front Oncol. 2022;12:998884.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu X, Jia J, et al. Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: a single center cohort study. Leuk Res Rep. 2022;18:100354.
   PubMedGoogle Scholar
• Dhakal P, Bates M, Tomasson MH, et al. Acute myeloid leukemia resistant to venetoclax-based therapy: what does the future hold? Blood Rev. 2022 Dec 1;59:101036.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pei Z, Wang H, et al. Chidamide and decitabine in combination with a HAG priming regimen for acute myeloid leukemia with TP53 mutation. Acta Med Okayama. 2022 Feb;76(1):63–70.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Zhou M, et al. Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro. Oncol Rep. 2022 Apr;47(4):66.
   PubMed Web of Science ®Google Scholar
• Wang L, Luo J, Chen G, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenetics. 2020 Sep 1;12(1):132.
   PubMed Web of Science ®Google Scholar
• Wang BR, Wan CL, Liu SB, et al. A combined histone deacetylases targeting strategy to overcome venetoclax plus azacitidine regimen resistance in acute myeloid leukaemia: three case reports. Front Oncol. 2021;11:797941.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu YC, Zhu CY, et al. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. J Exp Clin Cancer Res. 2020 Dec 9;39(1):278.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016 Aug 4;128(5):686–698.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian acute myeloid leukemia study group. Haematologica. 2015 Mar;100(3):324–330.
   PubMed Web of Science ®Google Scholar